Skip to content
20-F

Annual Report (Foreign)

NeuroSense Therapeutics Ltd. NRSN NRSNW

0001213900-26-036970

← back to feed
Filed
Mar 31, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 25.48M sh
Shares Diluted FY 2025 · Dec 31, 2024 18.6M sh
Shares Diluted FY 2025 · Dec 31, 2023 13.64M sh
Shares Outstanding FY 2025 · Dec 31, 2025 32.56M sh
Capex FY 2025 · Dec 31, 2025 $8K
Capex FY 2025 · Dec 31, 2024 $3K
Capex FY 2025 · Dec 31, 2023 $29K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$7.67M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$10.14M
Operating Cash Flow FY 2025 · Dec 31, 2023 −$8.35M
Cash And Equivalents FY 2025 · Dec 31, 2025 $166K
Cash And Equivalents FY 2025 · Dec 31, 2024 $3.38M
Stockholders Equity FY 2025 · Dec 31, 2025 −$1.56M
Stockholders Equity FY 2025 · Dec 31, 2024 $2.58M
Stockholders Equity FY 2025 · Dec 31, 2023 −$1.76M
Stockholders Equity FY 2025 · Dec 31, 2022 $5.84M
Current Liabilities FY 2025 · Dec 31, 2025 $2.52M
Current Liabilities FY 2025 · Dec 31, 2024 $1.99M
Total Liabilities FY 2025 · Dec 31, 2025 $2.59M
Total Liabilities FY 2025 · Dec 31, 2024 $1.99M
Current Assets FY 2025 · Dec 31, 2025 $778K
Current Assets FY 2025 · Dec 31, 2024 $4.4M
Total Assets FY 2025 · Dec 31, 2025 $1.03M
Total Assets FY 2025 · Dec 31, 2024 $4.58M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.44
Eps Diluted FY 2025 · Dec 31, 2024 −$0.54
Eps Diluted FY 2025 · Dec 31, 2023 −$0.74
Eps Basic FY 2025 · Dec 31, 2025 −$0.44
Eps Basic FY 2025 · Dec 31, 2024 −$0.54
Eps Basic FY 2025 · Dec 31, 2023 −$0.74
Sga Expense FY 2025 · Dec 31, 2025 $4.86M
Sga Expense FY 2025 · Dec 31, 2024 $4.2M
Sga Expense FY 2025 · Dec 31, 2023 $4.78M
Rd Expense FY 2025 · Dec 31, 2025 $6.23M
Rd Expense FY 2025 · Dec 31, 2024 $5.7M
Rd Expense FY 2025 · Dec 31, 2023 $7.27M
Net Income FY 2025 · Dec 31, 2025 −$11.13M
Net Income FY 2025 · Dec 31, 2024 −$10.21M
Net Income FY 2025 · Dec 31, 2023 −$10.11M
Operating Income FY 2025 · Dec 31, 2025 −$11.09M
Operating Income FY 2025 · Dec 31, 2024 −$9.9M
Operating Income FY 2025 · Dec 31, 2023 −$12.05M